Official Title
Remote Blood Pressure Monitoring With the Wearable SENBIOSYS Photoplethysmographic Device
Brief Summary

During the last couple of years, a growing number of wearable devices evolved to provide accurate, cheap and non-invasive monitoring of vitals parameters.This connected care technology could be helpful for treatment and care during a pandemic such as COVID-19. The use of these non-invasive remote monitoring devices can help health care providers to assess patient's vital signs and symptom progression, reducing reducing patient and healthcare provider contact and exposure to COVID-19 during this pandemic.

Detailed Description

Several cuff-less blood pressure monitoring devices have emerged in patient care using
photoplethysmography. PPG utilizes an infrared or visible light to measure peripheral
volumetric variations of blood circulation and its waveform has been proven to have a good
correlation with BP waveform.Nonetheless, the accuracy of these instruments is of fundamental
importance.

Several validation procedures for assessing the precision of BP monitoring devices have been
developed, including protocols by the Association for the Advancement of Medical
Instrumentation, International Organization for Standardization and European Society of
Hypertension. Adherence to these guidelines are essential to ensure the effectiveness of BP
measurement of the wearable devices.

Therefore, the investigators propose to test wearable low-noise, low-power SENBIOSYS
photoplethysmography signals for estimation of BP.

Completed
Blood Pressure

Device: Senbiosys

The patients will undergo blood pressure estimation as per clinical routine and will simultaneously wear the device.

Eligibility Criteria

Participants fulfilling the following inclusion criteria are eligible for the study:

- Age ≥ 18 years

- Patients referred for coronarography

- Patient in the intensive care unit requiring invasive blood pressure monitoring and
with an arterial catheter in place at the time of inclusion to the study

The presence of any of the following exclusion criteria will lead to exclusion of the
participant:

- Unable or unwilling to provide written informed consent

- Coronarography in patients with myocardial infarction

- Patient with suspected or certified COVID-infection

- Patients with atrial fibrillation

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Switzerland
Locations

University and hospital Fribourg
Fribourg, Switzerland

Stéphane Cook, MD, Study Chair
University of Freiburg

Stéphane Cook, Prof
NCT Number
Keywords
Blood Pressure
remote monitoring
Covid-19